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Abstract
Background: Cervical cancer is the most common cancer among women in Botswana and elsewhere in Sub-Saharan Africa.
We sought to examine whether HPV vaccine is acceptable among parents in Botswana, which recently licensed the vaccine
to prevent cervical cancer.
Methods and Findings: We conducted a cross-sectional survey in 2009, around the time the vaccine was first licensed, with
adults recruited in general medicine and HIV clinics in Gaborone, the capital of Botswana. Although only 9% (32/376) of
respondents had heard of HPV vaccine prior to the survey, 88% (329/376) said they definitely will have their adolescent
daughters receive HPV vaccine. Most respondents would get the vaccine for their daughters at a public or community clinic
(42%) or a gynecology or obstetrician’s office (39%), and 74% would get it for a daughter if it were available at her school.
Respondents were more likely to say that they definitely will get HPV vaccine for their daughters if they had less education
(OR=0.20, 95% CI=0.07–0.58) or lived more than 30 kilometers from the capital, Gaborone (OR=2.29, 95% CI=1.06–4.93).
Other correlates of acceptability were expecting to be involved in the decision to get HPV vaccine, thinking the vaccine
would be hard to obtain, and perceiving greater severity of HPV-related diseases.
Conclusions: HPV vaccination of adolescent girls would be highly acceptable if the vaccine became widely available to the
daughters of healthcare seeking parents in Gaborone, Botswana. Potential HPV vaccination campaigns should provide more
information about HPV and the vaccine as well as work to minimize barriers.
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Introduction
About 530,000 women are diagnosed with cervical cancer every
year worldwide, and about 275,000 women die from the disease
[1]. About 15% (80,000) of these diagnoses and 20% (53,000) of
these deaths occur in Africa, where cervical cancer screening and
treatment is much more limited than in the developed world [1].
Another important contributor to the cervical cancer burden in
Africa is the high prevalence of HIV, especially in Sub-Saharan
Africa (5%) [2]. Women with HIV are six times more likely to
develop cervical cancer compared to those not infected with HIV,
due to HIV-related immune suppression [3]. Many countries have
approved vaccines to prevent infection with human papillomavirus
(HPV), several strains of which can cause cervical cancer [4]. In
lower resource settings where cervical cancer screening and
treatment are scarce, delivery of the 3-dose HPV vaccine series
could provide women with ongoing protection, if it became widely
available at a low cost (e.g., if the Global Alliance for Vaccines and
Immunizations negotiates lower prices for the vaccine in
Botswana).
Early research in the US, Canada, Europe and Australia found
that correlates of HPV vaccine acceptability included the belief
that cervical cancer is a common and serious health threat, that
the vaccine is safe, effective and easy to obtain, and that a doctor
would recommend it, all constructs from the health belief model
[5]. More recent work has focused on HPV vaccine acceptability
in developing country settings such as Kenya, Latin America, the
Caribbean, Vietnam, Malaysia, China, and India [6–12]. While
these studies have generally found high acceptability of HPV
vaccine, few studies have quantitatively examined the acceptability
of HPV vaccine in Sub-Saharan Africa [6,13,14], and these studies
had limited information on respondents’ beliefs about the vaccine.
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limited cervical cancer screening program and high HIV burden,
both factors that contribute to high mortality from cervical cancer
[2,15,16]. The Botswana government licensed HPV vaccine in
2009 but, likely due to its relatively high cost, the vaccine is not yet
available in the public sector, where the majority of the population
accesses care. When HPV vaccine becomes available, the national
health plan may one day cover the vaccine, and it may also be
available sooner to some Botswana parents if they paid for it out of
pocket. The purpose of the present study was to examine HPV
vaccine acceptability for adolescent girls and its predictors among
healthcare-seeking adults in Gaborone, the capital of Botswana.
Based on the health belief model, we expected higher acceptability
of HPV vaccine among respondents who perceived cervical cancer
to be likely and severe, thought the vaccine would not be hard to
obtain, and would be recommended by a doctor.
Methods
Ethics Statement
The Institutional Review Boards at the University of Pennsyl-
vania, Princess Marina Hospital, and the Botswana Ministry of
Health approved this study and consent process for this study. We
obtained written and verbal consent from all participants.
Completion of the survey was considered documentation of verbal
consent. Participants received no monetary, food, or other
incentives for participating to minimize the possibility of coercion.
Participants and Procedures
We conducted a cross-sectional survey of parents’ and adults’
intentions to get HPV vaccine for adolescent daughters in
Gaborone, Botswana. In January 2009, we identified potential
participants from two free health clinics at Princess Marina
Hospital, the capital’s main government hospital. We recruited in
clinics associated with an existing Botswana-University of
Pennsylvania partnership due to limited resources. Both clinics
provided virtually free health care to citizens of Botswana and
charge a subsidised fee to non-citizens. Since January 2002,
Botswana has provided free highly active antiretroviral therapy
(HAART) to citizens who are HIV positive and who meet
specified clinical criteria.
Local Botswana high school graduates conducted interviews as
part of a capacity building collaboration with the Botswana
government. Interviewers received training about cervical cancer
and appropriate translations for medical terminology from a
Motswana obstetrics and gynecology physician. They memorized
scripts to achieve consistency during introductions, interviews, and
informed consent and received ongoing supervision throughout
the interview month. The three interviewers rotated among study
sites, and three experienced research nurses affiliated with the
Botswana-University of Pennsylvania Partnership provided super-
vision.
In the study clinics, patients queued up in a large general seating
area on a first come, first served basis. Each morning, a charge
nurse provided general clinic information to these patients.
Interviewers introduced the study in both English and Setswana
(a local language), describing the survey as being about individual
attitudes toward cervical cancer and new treatment options that
could affect adolescent girls. Interviewers asked patients interested
in volunteering to raise their hands and later obtained verbal
consent. Due to space constraints and concerns about participants
losing their spot in line, participants completed the survey in the
main waiting area.
We offered the five-page, self-administered paper and pencil
survey in either Setswana or English. Interviewers read each
survey question for the few individuals that self-identified as unable
to read or who preferred this option. Each day, interviewers
conducted a head count at each study site to estimate what
percentage of the population agreed to participate. We determined
sample size based on our ability to recruit for one month in clinics
in Gaborone as part of a capacity building exercise. An estimated
half of people attending the clinics on the days of the study
participated in the survey.
Measures
The surveys appear in the appendix (Text S1). We modified
survey items that we previously used in our HPV vaccine research
with US adolescent females, parents, and healthcare providers
[17–20]. We drafted our survey in English. A native Botswana
resident and a Motswana obstetrics and gynecology physician
translated the survey to Setswana and back translated it; we
resolved discrepancies through discussion.
Since many pilot participants knew little about HPV, HPV
vaccine, and cervical cancer, the survey provided basic informa-
tion on these topics. For example, the information on the vaccine
that appeared directly before the relevant HPV vaccine questions
read, ‘‘An HPV vaccine is now available that protects against most
genital warts and cervical cancer. Sometimes it’s called the cervical
cancer vaccine, HPV shot, Cervarix or Gardasil. We will call it the
HPV vaccine.’’ We tested the survey’s cultural appropriateness
and clarity with three Botswana women and made several
revisions to it.
The main outcome was willingness to vaccinate, assessed by a
question that asked how likely adults were to get HPV vaccine for
an adolescent daughter when it became available in Botswana.
The response options were ‘‘definitely will not,’’ ‘‘probably will
not,’’ ‘‘probably will,’’ and ‘‘definitely will’’. We classified each
participant as either definitely will get her or his daughter HPV
vaccine (=1) or other responses (=0). Instructions stated that
respondents who did not have an adolescent daughter should
answer the survey questions as if they did.
Statistical Methods
We use bivariate logistic regression models to examine bivariate
correlates of HPV vaccine acceptability. We report bivariate
analyses as exploratory multivariate models were unstable,
perhaps due to limited variability in the outcome measure and
our relatively small sample size. Less than 5% of data was missing
for any variable. We analyzed data using SPSS version 16.0 (SPSS
Inc., Chicago IL) and SAS version 9.2 (Cary, NC). All statistical
tests were two-tailed, using a critical alpha of 0.05.
Results
Most (77%) of the 376 survey respondents were female (Table 1).
Their median age was 37 years (range 20 to 84 years).
Respondents were distributed in similar proportions among three
education levels: 31% had completed a primary education (similar
to completing middle school or completing grade 6 in the US) or
had less education, 41% secondary education (similar to
completing high school in the US), and 28% tertiary education
and above. Most respondents had no regular income (48%) or
made less than US$360 (2500 pula) per month (29%), an amount
considered low income by Botswana federal government tax
brackets [21]. About two-thirds (65%) reported living within
30 kilometers of the capital, Gaborone. Most respondents had
children (83%), and of these parents, 77% had one or more
HPV Vaccine in Gaborone, Botswana
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(range, 10 months to 42 years). Of the 241 respondents who had
daughters, 71% had at least one daughter who was between the
ages of 11 and 26, meaning that she was in the age range
recommended to receive HPV vaccine.
About half (52%) of the respondents reported that they were
HIV-positive (Table 2). Some respondents reported a history of
sexually transmitted infections (23%) or genital warts (8%). Of
the 289 female respondents, 29% reported never having had a
previous Pap test, and 10% reported a previous diagnosis of
cervical cancer. About 45% of the respondents completed the
survey at the HIV clinic; nearly all (94%) of the respondents in
the HIV clinic reported that they were HIV-positive. HIV
clinic respondents were more likely than general medicine
clinic respondents to be HIV-positive, older, female, or less
educated, or to have had a sexually transmitted infection or
genital warts.
Cervical Cancer and HPV Vaccine
Many respondents had heard of cervical cancer (71%) or genital
warts (65%) prior to the survey. However, only about one-third
had heard of HPV (35%). The majority thought their daughters
had a moderate to high chance of getting genital warts (68%),
HPV (72%), or cervical cancer (78%) in their lifetime (Table 3).
About three-fourths rated these outcomes as severe or extremely
severe (72%, 75%, and 78%).
Prior to the survey, few respondents had heard of HPV vaccine
(9%), but most wanted more information about it (75%) (Table 4).
The majority reported that they would be involved a lot in the
decision to give HPV vaccine to their daughters (81%). Others
involved in the decision would be her doctor (58%), the parent’s
spouse or partner (45%), the daughter (34%), an elder (19%), or
other people (4%). Among respondents who said they would be
involved in the decision to vaccinate their daughters, almost all
(99%) said they would discuss the decision with them.
Table 1. Demographic characteristics (correlates of HPV vaccine acceptability for daughters).
No. definitely will get HPV vaccine for
daughter/total no. in category (%) Bivariate OR (95% CI)
Age
20–30 years 102/115 (89) ref.
31–84 years 226/257 (88) 0.93 (0.47–1.85)
Sex
Female 252/287 (88) ref.
Male 77/86 (90) 1.19 (0.55–2.58)
Marital Status
Never married 214/243 (88) ref.
Married/was married 114/129 (88) 1.03 (0.53–2.00)
Education
Primary or less 111/115 (97) ref.
More than primary 218/257 (85) 0.20 (0.07–0.58)*
Monthly income
No regular income 157/177 (89) ref.
,US$360 (2500 pula) 100/109 (92) 1.42 (0.62–3.23)
$US$360 (2500 pula) 69/84 (82) 0.59 (0.28–1.21)
Distance from capital (Gaborone)
0–29 km 202/237 (85) ref.
$30 km 119/128 (93) 2.29 (1.06–4.93)*
Children
No 54/64 (89) ref.
Yes, but no daughter 61/68 (90) 1.07 (0.35–3.24)
Yes, at least one daughter 211/241 (88) 0.86 (0.36–2.07)
Daughter in age range recommended to receive HPV vaccine
No 118/132 (89) ref.
Daughter outside of age range 61/70 (87) 0.80 (0.33–1.96)
Daughter ages 11 to 26 150/171 (88) 0.85 (0.41–1.74)
Study Site
HIV clinic 151/170 (89) ref.
General medicine clinic 178/203 (88) 0.90 (0.46–1.69)
Note. Counts do not add up to n=376 for some variables due to missing data. HPV=human papillomavirus, OR=odds ratio, CI=confidence interval, ref.=referent
group, HIV=human immunodeficiency virus.
*p,0.05.
doi:10.1371/journal.pone.0025481.t001
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get HPV vaccine for their adolescent daughters. Fewer said they
would definitely get it if a nurse recommended it than if a doctor
did (78% vs. 89%, p,.001). Eighty-two percent would definitely
give HPV vaccine to their daughters if it were available with other
childhood vaccines. Twenty-two percent believed their daughters
would be more likely or much more likely to have sex if they got
HPV vaccine. The median range that respondents said they would
be willing to pay for HPV vaccine was 21–50 pula (US$3.07-
US$7.30).
The most common place people would get the vaccine for their
daughters was a public or community clinic (42%), followed by a
Table 2. Personal health (correlates of HPV vaccine acceptability for daughters).
No. definitely will get HPV vaccine for
daughter/total no. in category (%) Bivariate OR (95% CI)
Had sexually transmitted infection
No 247/284 (87) ref.
Yes 77/84 (92) 1.65 (0.71–3.84)
Had genital warts
No 285/325 (88) ref.
Yes 28/31 (90) 1.31 (0.38–4.51)
Had cervical cancer
No 238/273 (87) ref.
Yes 29/30 (97) 4.27 (0.56–32.30)
HIV status
Negative (or never tested) 155/179 (87) ref.
Positive 173/193 (90) 1.34 (0.71–2.52)
Note. Counts do not add up to n=376 for some variables due to missing data. HPV=human papillomavirus, OR=odds ratio, CI=confidence interval, ref.=referent
group, HIV=human immunodeficiency virus.
*p,0.05.
doi:10.1371/journal.pone.0025481.t002
Table 3. Beliefs about HPV-related diseases.
No. definitely will get HPV vaccine for
daughter/total no. in category (%) Bivariate OR (95% CI)
Chance daughter will get HPV
Less than high 205/237 (87) ref.
High 121/133 (91) 1.57 (0.78–3.17)
Chance daughter will get genital warts
No, low or moderate 212/237 (89) ref.
High 107/123 (87) 1.23 (0.62–2.42)
Chance daughter will get cervical cancer
No, low or moderate 183/209 (88) ref.
High 142/160 (89) 1.12 (0.59–2.12)
Perceived severity of HPV infection for daughter
Less than high 77/91 (85) ref.
High 248/278 (89) 1.50 (0.76–2.98)
Perceived severity of genital warts for daughter
Less than high 86/104 (83) ref.
High or extremely high 240/265 (91) 2.01 (1.04–3.86)*
Perceived severity of cervical cancer for daughter
Less than high 64/80 (80) ref.
High or extremely high 260/288 (90) 2.32 (1.19–4.55)*
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available at their daughters’ schools, 74% would get it for them
there. Only 8% thought it would be hard or very hard to find a
clinic with HPV vaccine. The most common barriers that
respondents listed for getting HPV vaccine were ‘‘don’t know’’
(59%), difficulties accessing a clinic, healthcare provider, or the
vaccine (12%) and lack of information (10%).
Correlates of HPV Vaccine Acceptability
Respondents with more than a primary education were less
likely to say they would definitely get HPV vaccine for their
daughters than those with a primary education or less (OR=0.20,
95% CI=0.07–0.58) (See Tables 2, 3, 4). Those living more than
30 kilometers from the capital were more willing than respondents
living closer to or in the capital, Gaborone (OR=2.29, 95%
CI=1.06 to 4.93) and those responding that they would be
involved in the decision to get HPV vaccine were also more willing
than those not involved in the decision (OR=2.22, 95% CI=1.11
to 4.45). Participants that thought HPV vaccine would be hard to
obtain were less likely to say they will definitely get it for their
daughters compared to those that thought the vaccine would be
easy to obtain (OR=.51, 95% CI=.26 to .99). Finally, those that
perceived genital wart or cervical cancer as severe or very severe
compared to those that perceived such conditions as less than
severe were more willing to get HPV vaccine for their daughters
(OR=2.01, 95% CI=1.04 to 3.86 and OR=2.32, 95% CI=1.19
to 4.55).
Discussion
HPV vaccine acceptability was high among respondents in this
study of adults in Botswana, a middle-income African country with
a high rate of cervical cancer. The high acceptability is typical of
studies of acceptability of providing HPV vaccine to daughters [5]
[22], though it is somewhat counterintuitive given respondents’
low awareness of HPV and HPV vaccine prior to the study. Other
studies on HPV vaccine acceptability have shown similar findings.
Studies in Kisumu, Kenya and Mysore, India found that despite
limited knowledge about HPV vaccine, most parents were highly
accepting of having their daughters receive the vaccine [6,11].
Our findings suggest an important role for providing informa-
tion about the disease and interventions available to help
respondents and their daughters make informed decisions about
whether to get them HPV vaccine. Almost three-quarters of survey
participants wanted more information about HPV vaccine.
Furthermore, almost all respondents who would be involved in
the decision to vaccinate their daughters would discuss the decision
with her.
Efforts to spread information may wish to consider addressing
several health belief model constructs that were associated with
acceptability [18,23] Our respondents reported higher acceptabil-
ity if they believed two HPV-related conditions, genital warts and
cervical cancer, were serious health problems (i.e., perceived
severity), but beliefs about the chances of their daughter getting
these illnesses were not associated with interest in the vaccine (i.e.,
perceived likelihood). Acceptability was lower if they believed the
vaccine would be hard to obtain for their daughters, but potential
sexual disinhibition was not a concern (i.e., perceived barriers). A
recommendation from doctors was a more potent cue to action
than a recommendation from a nurse (i.e., cue to action).
Although the majority of respondents did not know what
barriers might prevent them from getting HPV vaccine, our study
revealed some possibilities. Given that the median amount that
participants were willing to pay for HPV vaccine was about US$5,
cost would likely be a major barrier if HPV vaccine was not
heavily subsidized or offered for free by the government.
Furthermore, although about 80% of participants said they would
get HPV vaccine at a clinic or gynecology office, nearly as many
were willing to get the vaccine at their daughters’ schools. Given
these findings and that HPV school-based vaccine clinics have
been successful elsewhere [24,25], programs should consider
schools as potential venues for HPV vaccine delivery in Botswana.
Schools have already been an effective delivery site for other
vaccines, and they may help families who have difficulties
accessing a clinic or healthcare provider to obtain HPV vaccine
for their daughters.
Table 4. Beliefs about HPV vaccine (correlates of HPV vaccine acceptability for daughters).
No. definitely will get HPV vaccine for
daughter/total no. in category (%) Bivariate OR (95% CI)
Wanted more information about HPV vaccine
Disagree 76/91 (84) ref.
Agree 251/279 (90) 1.77 (0.90–3.48)
Would be involved in decision to give HPV vaccine
No 57/71 (80) ref.
Yes 271/301 (90) 2.22 (1.11–4.45)*
Perception of difficulty obtaining HPV vaccine
Not hard 250/277 (90) ref.
Hard 75/91 (82) 0.51 (.26–.99)*
Believed HPV vaccine increases likelihood of sex
No 253/286 (88) ref.
Yes 72/82 (88) 0.93 (0.44–2.00)
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to vaccinate has also been shown in the United States [26], but this
is the first replication to our knowledge of this finding for HPV
vaccine in a developing country. The finding that participants
living further from the capital, typically in more rural areas, were
more willing to vaccinate their daughters than those living in the
urban capital has not been described previously in other countries
to our knowledge. The lower access to resources generally in rural
areas, and the consequences of having to travel for medical care,
may account for this higher interest.
Limitations
Study limitations include that the convenience sample of adults
seeking healthcare may not be representative of Botswana. These
individuals may have had different awareness of and access to
healthcare than the general population. Although we oversampled
HIV-positive persons (52% in our study vs. 24% national
prevalence in adults 15–49), results were similar when stratified
by HIV status (data not shown), suggesting that this oversampling
did not materially affect our results. Though HIV status was self-
reported, HIV prevalence in the general medicine clinic was
reasonably close to the national prevalence (17% vs. 24%),
providing some confidence that patients reported their HIV status
with reasonable accuracy. While some respondents did not have
daughters, we found no differences in HPV vaccine acceptability
among respondents with daughters compared to those with only
sons or no children.
Our survey results suggest that HPV vaccine would be an
accepted addition to routine care in Botswana that could play a
central role in cervical cancer prevention, but future studies should
also strive to include non-healthcare seeking individuals in both
rural and urban settings in Botswana and then replicate such
studies throughout sub-Saharan Africa. These studies should also
seek to determine the prevalent strains of HPV to determine what
percentage of those infected are at risk of developing cervical
cancer. Widespread uptake of the vaccine could help to mitigate
cervical cancer risk posed by very low rates of Pap testing and
condom use [2,27]. However, the feasibility of such action
depends in part upon the affordability of HPV vaccine which at
the time of our study was priced at US$360 for three doses, more
than the monthly salary of three-quarters of our survey
respondents [28]. The Global Alliance for Vaccines and
Immunizations (GAVI) is currently negotiating lower prices for
HPV vaccine in developing countries. If GAVI is successful and
Botswana qualified for GAVI pricing, Botswana could adopt HPV
vaccine into its multi-year plan for immunization and make it
widely available to women. Future studies should perform
comparative analyses of the costs of HPV vaccination versus
traditional cervical cancer screening methods to help national
programs in Botswana and elsewhere determine their relative
benefits. As Botswana has such a high incidence of cervical cancer
and cervical cancer has the highest mortality rate of all cancers in
Botswana, a successful HPV vaccination program could signifi-
cantly reduce cervical cancer morbidity and mortality [15].
Supporting Information
Text S1 Gaborone Children’s Health Study Question-
naire in English and Setswana.
(PDF)
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